Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00318656
Status:
COMPLETED
Last Update Posted:
2009-05-07
First Post:
2006-04-25
Brief Title:
24-Hour Glycemia Rosiglitazone Versus Glimepiride In Type 2 Diabetes
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Comparison of the Effects of Rosiglitazone and Glimepiride Both Given in Combination With Metformin on 24-Hour Glycemia in Type 2 Diabetes Patients Not Controlled With Metformin Alone A 3-Month Multicentre Randomized Parallel-Group Open-Label Study
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A better glycemic control is associated with less complications cardiac diseases blindness etcetera for type 2 diabetic patients The objective is to study if rosiglitazone may lead to a more regular glycemic pattern with less hyperglycemia and hypoglycemia episodes than with a sulphonylurea glimepiride
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AVAF4003 | None | None | None |